Amylyx Pharmaceuticals

Today, we announced we will proceed with cohort 2 enrollment in our LUMINA trial in #ALS following cohort 1 safety data demonstrating our investigational ASO was generally well-tolerated, with no treatment-related serious adverse events.     We look forward to presenting these data at the 36th International Symposium on ALS/MND. Learn more and see additional #alsmndsymp presentation details here: https://bit.ly/445x0Oo

Next week, our co-CEOs Justin Klee and Joshua Cohen are participating in the 2025 Advancing Drug Development Forum, where they’ll discuss what’s driving transformation right now in the Boston biotech hub and how to scale with strength, stability, and focus.    See more session details below. #ADDF2025 #BostonBiotech

Calpain-2 (CAPN2) is an important contributor to axonal degeneration, or nerve fiber damage, which plays a critical role in ALS progression. Research indicates that calpain-2 activation can disrupt key cellular pathways and reduce the structural integrity of nerve fibers, contributing to neurodegeneration. Learn more about the connection between calpain-2 and ALS on our website at https://www.amylyx.com/.

Sometimes, the first sign that something’s wrong isn’t a test but a nudge from a loved one. Maria’s dog Blue began alerting her to her hypoglycemic episodes before she even knew what was happening. Her family’s intuition and persistence led to a diagnosis of post-bariatric hypoglycemia (#PBH). At Amylyx, we’re committed to listening to and learning from those living with PBH. Watch Maria’s full story here: https://bit.ly/49yZVhe #PBHAwareness

Amylyx’ SVP of Medical Affairs, Jamie Timmons, MD, will be presenting this Saturday, November 15, at the Snow and Wolfram Syndrome UK Foundations Virtual Global Research and Trial Update. Dr. Timmons will share Week 48 results and updates from our Phase 2 open-label HELIOS clinical trial in adults living with #Wolframsyndrome. Learn more and register for the virtual event here: https://lnkd.in/ey4-xAqM

What we’re doing, why, and how we’re doing it is deeply interwoven. Learn more about each of the core values guiding #TeamAmylyx below.

There are no approved therapies for the approximately 160,000 people in the U.S. who have post-bariatric #hypoglycemia (#PBH). That’s roughly 8% of people who have undergone the two most common types of bariatric surgery, Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy, over the last decade. Learn more about this rare condition on our website at https://amylyx.com #PBHAwareness

Maria was told she wouldn’t survive another year without bariatric surgery. Her story begins with a life-saving bariatric surgery procedure, but her journey didn’t end there. Maria and her daughter Kelly shared how post-bariatric #hypoglycemia (#PBH) emerged unexpectedly, turning hope into a new fight for health. At Amylyx, we’re committed to listening to and learning from those living with PBH. Watch Maria’s full story here: https://bit.ly/3KSsZWG #PBHAwareness

Our commitment is more than just a promise to work with urgency; it’s a personal responsibility felt by members of #TeamAmylyx like Kelly Sorel. Learn more about our mission and focus: https://lnkd.in/ezX6sNig

We recently celebrated two more 5-year anniversaries here at Amylyx: Jamie Timmons and Tammy Sarnelli! Thank you both for your leadership and commitment to our mission to develop novel therapies for communities with high unmet needs.